Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

apotex inc. - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets - 875mg+125mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

apotex inc. - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets - 250mg+125mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

apotex inc. - amoxicillin (amoxicillin trihydrate), clavulanic acid (potassium clavulanate) - tablets - 500mg+125mg

United States - English - NLM (National Library of Medicine)

gentell inc - zinc oxide, petrolatum - gentell shield & protect moisture barrier cream forms a water-shedding shield thta helps soothe and protect dry or irritated skin. theraprutic against irritation from urine, feces, and other bodily secretions. sheild & protect leaves skin soft and smooth rather than irretated and greasy. ideal for sensitive skin.

Singapore - English - HSA (Health Sciences Authority)

nong's - granules

Singapore - English - HSA (Health Sciences Authority)

purapharm international (singapore) pte ltd - granules (internal use)

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pt. sari sihat (m) sdn. bhd. - kaempferia galanga; tamarindus indica; vetiveria zizanoides linn; trigonella foenum graecum; pogestemonis cablin folium; farina oryzae; eucalyptus alba flos; cortex massoia aromatica; cortex cinnamomum sintok -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

perusahaan jamu arjuna sdn. bhd. - cinnamomum zeylanicum; zingeber officinale; semen parkia roxburghii; semen coriandrum sativum; rhizoma zingeber minus; rhizoma languas galanga; rhizoma curcuma longa; prunus amigdalus dulcis; paramoria polyneura cortex; labisia pothoina radix; kaempferia galanga rhizoma; fructus quercus infectoria; fructus piper retrofractum; fructus piper nigrum; fructus piper cubeba; fructus foeniculum vulgare; curcuma xanthorriza rhizoma; cortex massoia aromatica; cortex alyxia lucida -

Canada - English - myHealthbox

ecolab -

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - infliximab - powder for concentrate for solution for infusion - infliximab 100 mg/vial - infliximab - * rheumatoid arthritis:remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as well as the improvement in physical function in:• adult patients with active disease when the response to disease modifying antirheumatic drugs (dmards),including methotrexate, has been inadequate.• adult patients with severe, active and progressive disease not previously treated with methotrexate or other dmards.in these patient populations, a reduction in the rate of the progression of joint damage, as measured by x ray,has been demonstrated.* ankylosing spondylitis:remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately to conventional therapy.* psoriatic arthritis:remsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when the response to previous dmard therapy has been inadequate.* remsima should be administered:• in combination with methotrexate• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated.infliximab has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by x ray in patients with polyarticular symmetrical subtypes of the disease.* psoriasis:remsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen ultra-violet a (puva)* adult crohn’s disease remsima is indicated for treatment :• of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.• treatment of fistulising, active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).* ulcerative colitis• remsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies.paediatric crohn’s diseaseremsima is indicated for treatment of severe, active crohn’s disease in children and adolescents aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. infliximab has been studied only in combination with conventional immunosuppressive therapy.paediatric ulcerative colitisremsima is indicated for treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6 mp or aza, or who are intolerant to or have medical contraindications for such therapies.